Patents by Inventor Susan Korsmeyer

Susan Korsmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabilized alpha helical peptides and uses thereof
    Patent number: 9273099
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: March 1, 2016
    Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, Gregory Verdine
  • Stabilized p53 peptides and uses thereof
    Patent number: 8889632
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: November 18, 2014
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Susan Korsmeyer
  • Stabilized alpha helical peptides and uses thereof
    Patent number: 8796418
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: August 5, 2014
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Loren D. Walensky, Gregory L. Verdine, Susan Korsmeyer
  • Stabilized alpha helical peptides and uses thereof
    Patent number: 8198405
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: June 12, 2012
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, legal representative, Gregory Verdine
  • STABILIZED ALPHA HELICAL PEPTIDES AND USES THEREOF
    Publication number: 20120082636
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Application
    Filed: October 4, 2011
    Publication date: April 5, 2012
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, Gregory Verdine
  • Inhibitors of Taspase1 protease activity
    Patent number: 7964700
    Abstract: A novel protease, Taspase1, is described. Taspase1 is involved in the cleavage of the myeloid/lymphoid or mixed-lineage leukemia (i.e., MLL) protein, which is required for proper HOX gene regulation. Diagnostic methods utilizing Taspase1 are provided, as well as inhibitors of Taspase1. Methods of using the inhibitors of Taspase1 are also described. For example an inhibitor of Taspase1 can be used to treat a cancer, e.g., leukemia, in a subject.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: June 21, 2011
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James J. D. Hsieh, Stanley J. Korsmeyer, Susan Korsmeyer, legal representative, Emily H. Y. Cheng
  • STABILIZED P53 PEPTIDES AND USES THEREOF
    Publication number: 20100168388
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Application
    Filed: January 31, 2008
    Publication date: July 1, 2010
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer, Susan Korsmeyer
  • Stabilized alpha helical peptides and uses thereof
    Patent number: 7723469
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: May 25, 2010
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, legal representative, Gregory Verdine
  • Stabilized Alpha Helical Peptides and Uses Thereof
    Publication number: 20090176964
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Application
    Filed: July 30, 2008
    Publication date: July 9, 2009
    Inventors: LOREN D. WALENSKY, STANLEY J. KORSMEYER, SUSAN KORSMEYER, GREGORY VERDINE
  • Stabilized Alpha Helical Peptides and Uses Thereof
    Publication number: 20090149630
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Application
    Filed: September 18, 2008
    Publication date: June 11, 2009
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, Gregory Verdine
  • Taspase1 and Methods of Use
    Publication number: 20080177034
    Abstract: A novel protease, Taspase1, is described. Taspase1 is involved in the cleavage of the myeloid/lymphoid or mixed-lineage leukemia (i.e., MLL) protein, which is required for proper HOX gene regulation. Diagnostic methods utilizing Taspase1 are provided, as well as inhibitors of Taspase1. Methods of using the inhibitors of Taspase1 are also described. For example an inhibitor of Taspase1 can be used to treat a cancer, e.g., leukemia, in a subject.
    Type: Application
    Filed: September 6, 2007
    Publication date: July 24, 2008
    Inventors: James J.D. Hsieh, Stanley J. Korsmeyer, Susan Korsmeyer, Emily H. Y. Cheng
  • Taspase1 and methods of use
    Publication number: 20060068482
    Abstract: A novel protease, Taspase1, is described. Taspase1 is involved in the cleavage of the MLL protein, which is required for proper HOX gene regulation. Diagnostic methods utilizing Taspase1 are provided, as well as inhibitors of Taspase1. Methods of using the inhibitors of Taspase1 are also described. For example an inhibitor of Taspase1 can be used to treat a cancer, e.g., leukemia, in a subject.
    Type: Application
    Filed: October 26, 2004
    Publication date: March 30, 2006
    Inventors: James Hsieh, Stanley Korsmeyer, Susan Korsmeyer, Emily Cheng
  • Stabilized alpha helical peptides and uses thereof
    Publication number: 20050250680
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Application
    Filed: November 5, 2004
    Publication date: November 10, 2005
    Inventors: Loren Walensky, Stanley Korsmeyer, Susan Korsmeyer, Gregory Verdin